Table 1.
Demographic and Clinical Characteristics
| CKD Cohort (N = 50) | |
|---|---|
| Age, y | 57.2 ± 16.1 |
| Female sex | 22 (44%) |
| Black | 16 (32%) |
| SBP, mm Hg | 132.6 ± 18.9 |
| Diabetes | 17 (34%) |
| ACEi/ARB use | 36 (72%) |
| Diuretic use | 21 (42%) |
| CKD stage (GFR category)a | |
| G1 (≥90 mL/min/1.73 m2) | 3 (6%) |
| G2 (60–89 mL/min/1.73 m2) | 4 (8%) |
| G3a (45–59 mL/min/1.73 m2) | 9 (18%) |
| G3b (30–44 mL/min/1.73 m2) | 16 (32%) |
| G4 (15–29 mL/min/1.73 m2) | 10 (20%) |
| G5 (<15 mL/min/1.73 m2) | 8 (16%) |
| CKD stage (albuminuria category) | |
| A1 (<30 mg/g) | 1 7 (34%) |
| A2 (30–300 mg/g) | 11 (22%) |
| A3 (>300 mg/g) | 22 (44%) |
| Presumed cause of CKD | |
| Diabetic nephropathy | 16 (32%) |
| Vascular/HTN | 14 (28%) |
| Lupus/glomerulonephritis | 6 (12%) |
| Nephrectomy | 5 (10%) |
| CAKUT/PKD | 3 (6%) |
| CNI toxicity | 2 (4%) |
| Idiopathic NS from MN, FSGS | 2 (4%) |
| Lithium toxicity | 1 (2%) |
| Unknown/otherb | 7 (14%) |
Note: Values for continuous variables given as mean ± standard deviation; values for categorical variables given as count (percentage).
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAKUT, congenital anomalies of the kidney and urinary tract; CKD, chronic kidney disease; CNI, calcineurin inhibitor; FSGS, focal segmental glomerulosclerosis; GFR, glomerular filtration rate; HTN, hypertension; MN, membranous nephropathy; NS, nephrotic syndrome; PKD, polycystic kidney disease; SBP, systolic blood pressure.
Staging based on serum creatinine level, CKD Epidemiology Collaboration equation from the first sample collection.
Includes chronic interstitial nephritis, Alport disease, and chronic lithium toxicity.